These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 27872103

  • 1. Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.
    Gannon PO, Baumgaertner P, Huber A, Iancu EM, Cagnon L, Abed Maillard S, Maby-El Hajjami H, Speiser DE, Rufer N.
    Clin Cancer Res; 2017 Jul 01; 23(13):3285-3296. PubMed ID: 27872103
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E, Höhn H, Necker A, Förster R, Karbach J, Freitag K, Neukirch C, Castelli C, Salter RD, Knuth A, Maeurer MJ.
    Int J Cancer; 2002 Mar 20; 98(3):376-88. PubMed ID: 11920589
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
    Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE.
    Eur J Immunol; 2012 Nov 20; 42(11):3049-61. PubMed ID: 22806397
    [Abstract] [Full Text] [Related]

  • 8. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
    Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF.
    J Immunother; 2010 Oct 20; 33(8):848-58. PubMed ID: 20842051
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J.
    Clin Cancer Res; 1999 Oct 20; 5(10):2756-65. PubMed ID: 10537339
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW, Fox BA, Urba WJ.
    Clin Cancer Res; 2004 Jan 15; 10(2):668-80. PubMed ID: 14760090
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.
    Cancer Res; 2006 Feb 15; 66(4):1912-6. PubMed ID: 16488988
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.
    Cancer J Sci Am; 1998 Feb 15; 4(5):316-23. PubMed ID: 9815296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.